Iksuda Therapeutics specializes in the development of antibody-drug conjugates (ADCs) designed to target difficult-to-treat cancers with enhanced tumor specificity. Their approach emphasizes the creation of class-leading ADCs by integrating multiple components and utilizing a multi-platform strategy to ensure optimal payload delivery tailored to specific tumor types. Iksuda's ADCs incorporate advanced tumor-selective release mechanisms, which enhance both anti-cancer efficacy and patient safety. The company employs proprietary technologies, such as their PermaLink bioconjugation platform, to achieve stable conjugation of payloads to antibodies, ensuring high therapeutic index and minimizing toxicity.

The company’s research and development efforts are supported by a world-class team of experts in ADC design and drug development. Iksuda's pipeline includes a variety of ADCs targeting known and novel antigens, with a focus on achieving clinically meaningful differentiation from existing therapies. Their innovative design principles involve the use of advanced cleavable linkers and a diverse portfolio of payloads, including DNA cross-linkers and protein alkylators, which are selected based on their mechanisms of action and compatibility with specific tumor characteristics. Iksuda is committed to advancing their ADC programs through clinical trials, with ongoing collaborations aimed at optimizing the development of these targeted therapies.

United Kingdom

Iksuda Therapeutics is a biotechnology company focussed on the development of a new generation of antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours.
Iksuda’s pipeline of ADCs is centred on a portfolio of non-prodrug/prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink® platform.

Cancer

Digestive System Diseases

Immune System Diseases

Lung Diseases

Lymphatic Diseases

Skin Diseases

Urogenital Diseases

Iksuda Therapeutics

Breast cancer

HER2-expressing cancers

IKS014

Antibodies

Biologics

B-cell lymphoma

IKS03

Gastric cancer

IKS04

Lung cancer

Ovarian cancer

Triple-negative breast cancer

IKS012

Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom

Europe - West

Antibody Drug Conjugates

Therapeutic

Iksuda Therapeutics

Company Details